Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aumolertinib DDI with Midazolam in NSCLC
NCT06926413Phase 1Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Feb 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Maximum Plasma Concentration (Cmax) of midazolam and 1-hydroxymidazolam at Day 1, Area Under the Curve (AUC0-t) of midazolam and 1-hydroxymidazolam at Day 1 and 1 more. Started Feb 2025; status: recruiting.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06926413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06926413.